Management Articles

Bariatric surgery is an efficient method ? to achieve significant weight loss for NASH/NAFLD, learn more from our management articles.

Meta-analysis: NAFLD and melatonin supplementation

Authors: Mansoori A, Salimi Z, Hosseini SA, et al.
Published in Complement Ther Med 2020
This meta-analysis was conducted to evaluate the effect of melatonin on liver indices in patients with NAFLD. The results showed that melatonin had a significant effect on aspartate aminoteransferase , alkaline phosphatase, and gamma-glutamyltransferase, but no significant effect on alanine aminotransferase...
Read More

Emerging drugs targeting specific points in NASH pathogenesis

Authors: Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L,
et al.
Published in J Clin Transl Hepatol 2021
Extensive research and revelation in the field of pathogenesis of NASH has offered new possibilities of treatment and emerging new drugs that are being tested currently in numerous preclinical and clinical trials. These drugs target almost all steps in the pathogenesis of NASH...
Read More

The Significance of the Mediterranean Diet in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review

Authors: Gosal H, Kaur H, Chakwop Ngassa H, et al.
Published in Cureus 2021
In this systematic review, H. Gosal et al. (California Institute of Behavioral Neurosciences & Psychology, USA & Government Medical College, Amritsar, India) reviewed the effectiveness of the Mediterranean diet on NAFLD and its efficacy in disease management...
Read More

Pharmacotherapy in NAFLD/NASH

Authors: Attia SL, Softic S, Mouzaki M.
Published in Clin Transl Sci 2021
This review by SL Attia et al. (University of Kentucky College of Medicine, USA) summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD. Investigated pharmacotherapies include lanifibranor (IVA337), an indole sulfonamide PPAR agonist that activates....
Read More

European NAFLD guidelines: limitations when applied to T2D patients

Authors: Besutti G, Bonilauri L, Manicardi E, et al.
Published in Diabetes Res Clin Pract 2021
G. Besutti et al. aimed to evaluate the feasibility and efficiency of a guidelines-compliant NAFLD assessment algorithm in patients with newly diagnosed type 2 diabetes. Consecutive patients newly diagnosed with T2D without coexisting liver disease or excessive alcohol consumption were enrolled. They were stratified...
Read More

NAFLD/NASH-related liver fibrosis: mechanisms, treatment, and prevention

Authors: Tacke F, Weiskirchen R.
Published in Ann Transl Med 2021
NAFLD or NASH are nowadays the leading causes of hepatic fibrosis worldwide. In their review, F. Tacke (Charité University Medicine, Berlin, Germany) and R. Weiskirchen (RWTH University Hospital, Aachen, Germany) discuss recent advances in antifibrotic prevention and therapy....
Read More

Immunotherapy-treated HCC: NASH limits anti-tumour surveillance

Authors: Pfister D, Nunez NG, Pinyol R, et al
Published in Nature 2021
Immunotherapy has been approved for treating hepatocellular carcinoma (HCC), but biomarker-based stratification of patients for optimal response to therapy is an unmet need. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) did not lead...
Read More

Fibrosis in NASH: targeted therapies

Authors: Huisman TM, Dieterich DT, Friedman SL
Published in J Exp Pharmacol 2021
Progress in uncovering pathogenic determinants of fibrosis in NASH include metabolic dysregulation in hepatocytes that induce inflammation and cytokine secretion leading to cell injury and apoptosis, among others.This review by T. M. Huisman et al. (Division of Liver Diseases, Icahn School of Medicine at Mount Sinai...
Read More

Management of NAFLD: a review

Authors: Petroni ML, Brodosi L, Bugianesi E, et al.
Published in BMJ 2021
As explained in the review by M. L. Petroni et al. (“Alma Mater” University, Bologna, Italy), several drugs are under investigation according to the agreed targets of reduced NASH activity without worsening of fibrosis or improving fibrosis without worsening of NASH. Anti-inflammatory, anti-fibrotic agents and metabolism modulators...
Read More

Comparative analysis of different guidelines

Authors: LAndo Y, Jou JH
Published in Clin Liver Dis (Hoboken) 2021
In their review, Y. Ando and J. H. Jou (Oregon Health & Science University Hospital, Portland, Oregon, USA) summaries updated guideline and guidance recommendations for the management of adult NAFLD. They highlight key difference between US, Asian, and European recommendations; and provide key updates...
Read More

Is Europe ready to meet the challenge of fatty liver disease?

Authors: Lazarus JV, Palayew A, Carrieri P, et al
Published in JHEP Rep 2021
NAFLD is closely associated with obesity, metabolic syndrome, and diabetes. NAFLD can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures. NAFLD preparedness means having adequate policies and civil society...
Read More

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES